NH drug info case begins

Share this article:
IMS Health and Verispan will seek to protect the right to market prescription data from pharmacies in a case beginning this week. The research firms are bringing the case in US District Court in New Hampshire in the hope of striking down a law that took effect in the state last August, the Prescription Privacy Protection Act. The case’s outcome could set a precedent for states such as Nebraska, Nevada and Missouri, which have introduced copycat bills. New York is expected to do so this year. By banning the commercial use of prescription audit data, the act is designed to stop pharmaceutical sales people from influencing physicians’ medical decisions as well as help cut healthcare costs by leading to prescribing of less expensive drugs, say proponents. Under an exemption in the law, organizations can use the information as long as they do not profit from it. IMS and Verispan argue that the act restricts the flow of essential prescriber information and that it violates First Amendment free-speech protections. New Hampshire Rep. Cindy Rosenwald introduced the bill after her husband, a cardiologist, complained of being targeted by a sales rep.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...